Back to matchesWe found a matchYour institution may have rights to this item. Sign in to continue.TitlePhase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors.AuthorsDenlinger, Crystal S.; Keedy, Vicki L.; Moyo, Victor; MacBeath, Gavin; Shapiro, Geoffrey I.PublicationInvestigational New Drugs, 2021, Vol 39, Issue 6, p1604ISSN0167-6997Publication typeArticleDOI10.1007/s10637-021-01145-y